Literature DB >> 16154717

Role for mitogen-activated protein kinases in phenobarbital-induced expression of cytochrome P450 2B in primary cultures of rat hepatocytes.

Florence Joannard1, Mary Rissel, David Gilot, Alan Anderson, Luz Orfila-Lefeuvre, André Guillouzo, Azzedine Atfi, Dominique Lagadic-Gossmann.   

Abstract

Phenobarbital (PB) alters expression of numerous hepatic genes, including genes of cytochrome P450 2B1 and 2B2 (CYP2B). However, the intracellular mechanisms remain to be fully elucidated. The present study investigated the involvement of mitogen-activated protein kinases (MAPKs) in rat hepatocytes in primary culture. We showed that PB induced an early, dose-dependent activation of ERK (extracellular signal-regulated kinase), JNK (c-Jun N-terminal kinase) and p38 MAPKs. Regarding the PB (1mM) induction of CYP2B mRNA expression, while chemically inhibiting JNK had no effect, specific inhibitors of the ERK (U0-126) and p38 (SB-203580) pathways up- and down-regulated this expression, respectively. However, although such a regulation was confirmed when testing the effect of a dominant negative mutant of the ERK pathway on the CYP2B2 enhancer-promoter activity, no such transcriptional role was found with the p38 pathway. Moreover, upon arrest of transcription, the stability of CYP2B mRNA remained unaffected by SB-203580. In conclusion, we show that the ERK pathway negatively regulates CYP2B2 enhancer-promoter activity and that, despite p38 activation upon PB exposure, the sensitivity of CYP2B mRNA expression to SB-203580 appears to be unrelated to this kinase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16154717     DOI: 10.1016/j.toxlet.2005.08.006

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  12 in total

1.  MAPK-directed activation of the whitefly transcription factor CREB leads to P450-mediated imidacloprid resistance.

Authors:  Xin Yang; Shun Deng; Xuegao Wei; Jing Yang; Qiannan Zhao; Cheng Yin; Tianhua Du; Zhaojiang Guo; Jixing Xia; Zezhong Yang; Wen Xie; Shaoli Wang; Qingjun Wu; Fengshan Yang; Xuguo Zhou; Ralf Nauen; Chris Bass; Youjun Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-23       Impact factor: 11.205

Review 2.  Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease.

Authors:  Jeff L Staudinger; Kristin Lichti
Journal:  Mol Pharm       Date:  2007-12-27       Impact factor: 4.939

Review 3.  Small-molecule modulators of PXR and CAR.

Authors:  Sergio C Chai; Milu T Cherian; Yue-Ming Wang; Taosheng Chen
Journal:  Biochim Biophys Acta       Date:  2016-02-24

Review 4.  Mechanisms of xenobiotic receptor activation: Direct vs. indirect.

Authors:  Bryan Mackowiak; Hongbing Wang
Journal:  Biochim Biophys Acta       Date:  2016-02-10

5.  A physiological role of AMP-activated protein kinase in phenobarbital-mediated constitutive androstane receptor activation and CYP2B induction.

Authors:  Sawako Shindo; Satoshi Numazawa; Takemi Yoshida
Journal:  Biochem J       Date:  2007-02-01       Impact factor: 3.857

Review 6.  Role of CAR and PXR in xenobiotic sensing and metabolism.

Authors:  Yue-Ming Wang; Su Sien Ong; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-05-03       Impact factor: 4.481

7.  Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes.

Authors:  Chika Koike; Rick Moore; Masahiko Negishi
Journal:  Mol Pharmacol       Date:  2007-02-21       Impact factor: 4.436

8.  p38 Mitogen-activated protein kinase regulates nuclear receptor CAR that activates the CYP2B6 gene.

Authors:  Kosuke Saito; Rick Moore; Masahiko Negishi
Journal:  Drug Metab Dispos       Date:  2013-03-28       Impact factor: 3.922

9.  The Nrf2 activator oltipraz also activates the constitutive androstane receptor.

Authors:  Matthew D Merrell; Jonathan P Jackson; Lisa M Augustine; Craig D Fisher; Angela L Slitt; Jonathan M Maher; Wendong Huang; David D Moore; Youcai Zhang; Curtis D Klaassen; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2008-05-12       Impact factor: 3.922

Review 10.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.